Fate Therapeutics (FATE) Tops Q4 EPS by 7c

Fate Therapeutics (NASDAQ: FATE) reported Q4 EPS of ($0.45), $0.07 better than the analyst estimate of ($0.52). Revenue for the quarter came in at $1.7 million versus the consensus estimate of $1.62 million.

For earnings history and earnings-related data on Fate Therapeutics (FATE) click here.

You May Also Be Interested In

• Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
• Sun Communities names Ileana McAlary as general counsel and EVP
• Jefferies Reinstates Talen Energy (TLN) at Hold